A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy

Histologic transformation from non-small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a craniotomy to resect a brain metastasis, which was pathologically diagnosed as SCLC. He subsequently received platinum-based chemotherapy with durvalumab, resulting in sustained regression of the liver metastases. This case demonstrates a metastatic brain tumor-acquired resistance to atezolizumab through histologic transformation from adenocarcinoma to SCLC. Therefore, rebiopsy is needed if recurrent disease appears during immune checkpoint inhibitor treatment in patients with non-small cell lung cancer.

Authors

Institutions

Publication Details

Journal
Thoracic Cancer
Published
2024-12-27
DOI
https://doi.org/10.1111/1759-7714.15512
Citations
2
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy

Tomomi Masuda, Rei Yamaguchi, Sohei Muto, Hayato Ikota et al.
2 citations
Thoracic Cancer
Lung Cancer Research Studies
0.57
article

A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy

Tomomi Masuda, Rei Yamaguchi, Sohei Muto, Hayato Ikota, Noriaki Sunaga, Nobuteru Kubo, Yasuhiko Koga, Toshiteru Nagashima, Hiroaki Tsurumaki, Nao Kobayashi, Ikuo Wakamatsu, Masakiyo Yatomi, Yoichi Ohtaki, Toshitaka Maeno, Takeshi Hisada, Yosuke Miura, Reiko Sakurai
article en
2 citations

Abstract

Histologic transformation from non-small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a craniotomy to resect a brain metastasis, which was pathologically diagnosed as SCLC. He subsequently received platinum-based chemotherapy with durvalumab, resulting in sustained regression of the liver metastases. This case demonstrates a metastatic brain tumor-acquired resistance to atezolizumab through histologic transformation from adenocarcinoma to SCLC. Therefore, rebiopsy is needed if recurrent disease appears during immune checkpoint inhibitor treatment in patients with non-small cell lung cancer.

Thoracic CancerVol. 16(2)
Gunma University (JP), Gunma University Hospital (JP)
Good health and well-being
Openalex Percentile: Top 26%
Lung Cancer Research Studies
0.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.